FindTrial
Sign In

Randomized control trial of primary eradication therapies of Helicobacter pylori

Randomized control trial of primary eradication therapies of Helicobacter pylori - RAC versus LAC study

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001197
Enrollment
240
Registered
2008-07-01
Start date
2007-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroduodenal ulcer infected by Helicobacter pylori

Interventions

rabeprazole 10mg bid, amoxicillin 750mg bid and clarithromycin 200mg bid lansoprazole 30mg bid, amoxicillin 750mg bid and clarithromycin 200mg bid

Sponsors

University of Tokyo Hospital Department of Gastroenterology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who fills everything the following 1)Patients with gastric or duodenal ulcer 2)Patients infected by Helicobacter pylori, confirmed by bacterial culture test or rapid urease test or urea breath test 3)Patients of 20 years or more 4)Patients who gives written informed consent

Exclusion criteria

Exclusion criteria: 1)Pregnant females 2)Lacting woman 3)Patients who has past history of allergy for the drugs used in this study 4)Patients who has coexisting severe disease 5)Patient whom examination doctor judged improper as testee

Design outcomes

Primary

MeasureTime frame
Assessment of the Helicobacter pylori eradication on the bassis of the urea breath test result—

Secondary

MeasureTime frame
Influence of the clarithromycin resistance of Helicobacter pylori and the CYP2C19 genotype of the host for the eradication thrapies—

Countries

Japan

Contacts

Public ContactMasao Akanuma

The University of Tokyo Hospital Department of Gastroenterology

makanuma@qd6.so-net.ne.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026